CAMP4 Therapeutics (CAMP)
Antisense RNA medicines designed to restore protein expression in genetic diseases.
$3.83
Pre-market+0.03 (+0.79%)
At close$3.80(+0.26%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions47 holders · as of Mar 31, 2026 | 63.40% | 39.78M shares | |
| Insiders12 holders · as of Sep 2, 2026 | 9.34% | 5.86M shares | |
| Strategic holders3 holders · as of Aug 19, 2026 | 12.40% | 7.78M shares | |
| Otherremainder | 14.86% | 9.32M shares |
62.75M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (62.75M in the company's Sep 3, 2026 report, 21.24M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
47 holders · 39.78M shares · 16 new positions · 30 increased · 9 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 6.31M | 10.05% | 0 | May 18, 2026 |
| 5Am Venture Management, LLC | 5.87M | 9.35% | 0 | May 15, 2026 |
| FMR LLC | 4.93M | 7.86% | +15.2K | May 15, 2026 |
| Vivo Capital, LLC | 4.25M | 6.77% | 0 | May 20, 2026 |
| Balyasny Asset Management L.P. | 2.63M | 4.19% | +195.5K | May 15, 2026 |
| Enavate Sciences GP, LLC | 2.19M | 3.49% | −844.9K | May 15, 2026 |
| Ah Capital Management, L.L.C. | 2.13M | 3.39% | 0 | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 1.96M | 3.12% | −220.9K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 12.20% | 6.31M | 13G | Jan 8, 2026 ↗ |
| Marc Andreessenincl. AH Equity Partners Bio IV, L.L.C., Benjamin Horowitz +3 more | 10.90% | 2.13M | 13G | Oct 22, 2024 ↗ |
| Coastlands Capital LP | 9.99% | 4.89M | 13G | Dec 11, 2025 ↗ |
| Andrew J. Schwabincl. 5AM Ventures VI, L.P., Kush Parmar +5 more | 9.90% | 6.38M | 13D | Aug 31, 2026 ↗ |
| FMR LLC | 9.50% | 4.92M | 13G | Feb 5, 2026 ↗ |
| Vivo Opportunity Fund Holdings, L.P. | 7.40% | 3.86M | 13G | Feb 13, 2026 ↗ |
| Amir Nashatincl. Polaris Entrepreneurs' Fund VII, L.P., Amy Schulman +5 more | 6.30% | 3.93M | 13D | Aug 19, 2026 ↗ |
| Trails Edge Capital Partners, LP | 6.00% | 3.79M | 13G | Aug 10, 2026 ↗ |
| Balyasny Asset Management L.P. | 5.07% | 2.63M | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Kelly Goldofficer: Chief Financial Officer | Purchase | 10,000 | $3.96 | 10,000 |
| Aug 27, 2026 | Andrew J. Schwabdirector | Sale | 400,000 | $4.04 | 2,033,270 |
| Aug 24, 2026 | Andrew J. Schwabdirector | Sale | 10 | $4.50 | 2,433,270 |
| Aug 21, 2026 | Andrew J. Schwabdirector | Sale | 32,018 | $4.50 | 2,433,280 |
| Aug 20, 2026 | Andrew J. Schwabdirector | Sale | 114,700 | $4.54 | 2,465,298 |
| Aug 19, 2026 | Andrew J. Schwabdirector | Sale | 45,147 | $4.76 | 2,579,998 |
| Aug 19, 2026 | Daniel Tardiffofficer: Chief Scientific Officer | Sale | 1,738 | $4.76 | 0 |
| Aug 3, 2026 | Josh Mandel-Brehmdirector, officer: Chief Executive Officer | Purchase | 6,551 | $1.65 | 284,968 |
| Aug 3, 2026 | Kelly Goldofficer: Chief Financial Officer | Purchase | 6,551 | $1.65 | 74,428 |
| Aug 3, 2026 | Yuri Maricichofficer: Chief Medical Officer | Purchase | 6,551 | $1.65 | 12,611 |
CongressHouse and Senate disclosures
Not reported.